Nanobiotix S.A. (EPA:NANO)
3.244
-0.056 (-1.70%)
Apr 1, 2025, 12:42 PM CET
Nanobiotix Revenue
Nanobiotix had revenue of 9.29M EUR in the half year ending June 30, 2024, with 598.95% growth. This brings the company's revenue in the last twelve months to 42.20M, up 526.17% year-over-year. In the year 2023, Nanobiotix had annual revenue of 36.21M with 658.12% growth.
Revenue (ttm)
42.20M
Revenue Growth
+526.17%
P/S Ratio
3.36
Revenue / Employee
383.67K
Employees
102
Market Cap
156.44M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 44.29B |
EssilorLuxottica Société anonyme | 26.51B |
Sartorius Stedim Biotech | 2.78B |
bioMérieux | 3.98B |
Eurofins Scientific SE | 6.95B |
Ipsen | 3.57B |
Virbac | 1.40B |
emeis Société anonyme | 5.43B |
Nanobiotix News
- 1 day ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire
- 4 days ago - Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC - GlobeNewsWire
- 11 days ago - NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference - GlobeNewsWire
- 13 days ago - Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden - Benzinga
- 14 days ago - NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 - GlobeNewsWire
- 6 weeks ago - Baillie Gifford's Strategic Acquisition of Nanobiotix SA Shares - GuruFocus
- 2 months ago - Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - GlobeNewsWire